Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2012

View Archived Issues

Intravaginal ring technology gains attention for HIV prevention / News in Context

Almirall describes novel SYK inhibitors at ongoing ACS meeting

In-fiber method allows scalable production of uniform structured spheres for drug delivery

FDA grants orphan drug status to mondoBIOTECH product

Dainippon Sumitomo Pharma establishes new oncology institute

New sildenafil formulation launched in Korea to treat erectile dysfunction

Abbott to launch next-generation drug-eluting stent

Pivotal BEMA-buprenorphine/naloxone trial advances

Treatment begins in trial of JVS-100 for late-stage heart failure

Gilead Sciences presents new candidate therapeutics for hepatitis

Novartis divulges new glutamate receptor antagonists

New cathepsin A inhibitors patented by Sanofi

Collaboration yields novel prostanoid EP1 receptor antagonists

Proximagen discloses novel PAR2 receptor antagonists

Novel prostanoid FP receptor agonists designed in Japan

Investigational BCR-ABL inhibitor enters new phase I/II trial in Japan

Novel IL-17A/IL-17F inhibitors identified at 4SC

New mutation linked to persistent hyperplasia of the primary vitreous

FDA requests additional information for MoxDuo NDA

U.S. university and Novartis launch exclusive licensing agreement

Alligator Bioscience enters agreement with biotech company

Inspiration Biopharmaceuticals and Ipsen restructure strategic alliance

Travoprost punctum plug for glaucoma advances to phase II

New lotion against head lice launched in U.S.

FDA approves new dosages of sublingual film for opioid dependence

Kineta clear to move first K(V)1.3 channel-specific antagonist into clinic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...